Gilead Sciences Inc. bought Kite Pharma (USD 11.9 Billion) while Celgene took over Juno Therapeutics (USD 9 Billion) to make the greatest speculation into this rising subject over the recent one year. While experts hope that each individual CAR-T therapies will yield sales of USD 1 billion, the investing companies hope to rope in higher sales. With the death of five patients in the trials of Juno Therapeutics, Seattle Biotech now assumes its CAR-T cell therapy to be the best in class. While the equipment makers are now independent and are making their own inventions in CAR-T cell therapy, bigger companies are also getting involved in this business like GE Healthcare investing in cold chain experts etc. These advancements will bring in more deals for the development of cellular therapies and will further help the patients get better access to treatment with minimal side effects. However, there are few limitations to be taken into consideration such as cost-effectiveness and therapy limited to specific bloodlines.
DelveInsight Blog
Related Article
![pharma-news-for-alnylam-bms-daichii-sankyo-vertex pharma-news-for-alnylam-bms-daichii-sankyo-vertex](https://assets.delveinsight.com/blog/wp-content/uploads/2024/06/25155241/pharma-news-for-alnylam-bms-daichii-sankyo-vertex.png)
Alnylam’s HELIOS-B Phase III Study of Vutrisiran; Bristol Myers Squibb Secures FDA Nod for KRAZATI and Cetuximab; Daichii Sankyo’s EZHARMIA® Receives Japan Approval; Vertex’s Phase I/II VX-880 Trial; argenx’s VYVGART Hytrulo FDA Approval
Alnylam's HELIOS-B Phase III Study of Vutrisiran Shows Positive Results, Meeting All Primary and Secondary Endpoints Alnylam Pharmaceuticals, Inc. reported encouraging topline outcomes from its HELIOS-B Phase III study of vutrisiran, an experimental RNAi therapy being developed to treat ATTR amyloidosis with car...
Find More![pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms](https://assets.delveinsight.com/blog/wp-content/uploads/2024/06/18150914/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms.png)
Takeda Showcase Phase III Results for Soticlestat; Imfinzi and Chemotherapy Combination Gains US Approval; Nipocalimab Shows Notable Efficacy in Phase II Study; Bristol Myers Squibb’s Augtyro FDA Approval; AstraZeneca’s Farxiga FDA Approval
Takeda Reveals Phase III Results for Soticlestat (TAK-935) in Dravet and Lennox-Gastaut Syndromes Takeda revealed topline results from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase III trial assessing soticlestat (TAK-935) plus standard care against plac...
Find More![pharma-news-for-moderna-almirall-lilly-ipsen pharma-news-for-moderna-almirall-lilly-ipsen](https://assets.delveinsight.com/blog/wp-content/uploads/2024/06/11141344/pharma-news-for-moderna-almirall-lilly-ipsen.png)
Moderna’s Phase III Trials for Dual Influenza and COVID-19 Vaccine; Almirall’s Klisyri FDA Approval; Lilly’s Tirzepatide MASH Trial; Cycle Pharmaceuticals Acquisition of Vanda Pharmaceuticals; Ipsen’s Iqirvo FDA Approval
Moderna Reports Successful Phase III Trials for Dual Influenza and COVID-19 Vaccine Moderna, Inc. has reported that its Phase III trial for mRNA-1083, an experimental combination vaccine targeting both influenza and COVID-19, achieved its main objectives by generating a stronger immune response than the approved...
Find MoreEditor's Pick
Newsletter/Whitepaper
Recent Article
ASCO Conference 2024
![ASCO 2023 ASCO 2023](https://assets.delveinsight.com/img/events/american-society-of-clinical-oncology-conference-2024.png)
Live Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!